Tesamorelin: Clinical Evidence on Visceral and Liver Fat in Studied HIV Populations

Research brief

Tesamorelin, a growth hormone-releasing hormone analogue, has shown efficacy in reducing visceral and liver adipose tissues in people with HIV and lipodystrophy receiving antiretroviral therapy. Current evidence focuses on this specific population, necessitating further studies for broader applicability and long-term effects [PMID: 42538058; PMID: 41545261].

Key findings

• Tesamorelin reduces visceral adipose tissue significantly in HIV populations with lipodystrophy [PMID: 42538058]. • It shows promising effects on decreasing liver fat and improving body composition [PMID: 41545261; PMID: 38905488]. • Growth hormone-related side effects are reported, and more research is needed for long-term safety assessments [PMID: 42538058]. • Increased lean body mass was observed in a study population [PMID: 31237318].

Detailed research context

Introduction

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue specifically studied in people living with HIV (PLWH) who experience lipodystrophy as a complication of their antiretroviral therapy [PMID: 42538058]. As lipodystrophy can lead to visceral fat buildup and various health issues, addressing this condition is paramount for improving patient outcomes.

Study Populations

Research has predominantly focused on HIV-infected individuals undergoing antiretroviral therapy and dealing with resultant lipodystrophy. Tesamorelin was studied in various randomized controlled trials with such populations, often involving individuals across multiple sites in North America [PMID: 31237318; PMID: 41545261].

Efficacy in Reducing Visceral and Liver Fat

Evidence from several studies indicates that Tesamorelin is effective in reducing visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy. A systematic review and meta-analysis concluded that Tesamorelin significantly reduced visceral adipose tissue with a mean difference of -21.47 [95% CI[-34.73, -8.22],p=0.002] [PMID: 42538058]. Further, it also impacted liver fat positively, reducing hepatic fat percentage significantly in several trials [PMID: 41545261; PMID: 38905488].

Impact on Muscle and Body Composition

Promising results were shown in increasing lean body mass, as evidenced by a significant rise (MD=1.42kg, 95% CI[1.13,1.71]; p<0.001) among test populations [PMID: 41545261]. A secondary analysis revealed improvements in muscle fat and area, showcasing beneficial effects beyond visceral fat reduction [PMID: 31237318].

Adverse Effects and Safety Concerns

While Tesamorelin demonstrates a favorable impact on body composition, various growth hormone-related adverse effects have been noted, including arthralgia, myalgia, and injection-site reactions. These adverse effects underline the need for careful consideration and further research into the long-term safety of this treatment [[PMID: 41545261]].

Unresolved Questions and Future Directions

Current research highlights Tesamorelin's capacity to reduce VAT and improve liver health in HIV-infected individuals with lipodystrophy. However, more data are needed to ascertain long-term safety, dosage strategies, and durability of effects. Additionally, patient-reported outcomes and metabolic markers warrant further investigation to establish broader clinical recommendations [PMID: 42538058; PMID: 41545261].

Conclusion

Tesamorelin offers a targeted approach to managing lipodystrophy-related visceral obesity in HIV populations on ART regimens. While beneficial changes in body composition are evident, continued studies to explore comprehensive treatment regimens and safety profiles are essential to maximize patient benefit and safeguard against potential complications.

Source method

This research briefing is based on the verified PubMed records linked in the References & Citations section below.